RU2016133965A3 - - Google Patents

Download PDF

Info

Publication number
RU2016133965A3
RU2016133965A3 RU2016133965A RU2016133965A RU2016133965A3 RU 2016133965 A3 RU2016133965 A3 RU 2016133965A3 RU 2016133965 A RU2016133965 A RU 2016133965A RU 2016133965 A RU2016133965 A RU 2016133965A RU 2016133965 A3 RU2016133965 A3 RU 2016133965A3
Authority
RU
Russia
Application number
RU2016133965A
Other languages
Russian (ru)
Other versions
RU2711452C2 (ru
RU2016133965A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016133965A publication Critical patent/RU2016133965A/ru
Publication of RU2016133965A3 publication Critical patent/RU2016133965A3/ru
Application granted granted Critical
Publication of RU2711452C2 publication Critical patent/RU2711452C2/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2016133965A 2014-01-22 2015-01-21 Усовершенствованная стратификация пациентов для оценки пригодности терапии RU2711452C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14152183 2014-01-22
EP14152183.1 2014-01-22
PCT/EP2015/051051 WO2015110440A1 (fr) 2014-01-22 2015-01-21 Stratification améliorée de patients pour évaluer la convenance d'une thérapie

Publications (3)

Publication Number Publication Date
RU2016133965A RU2016133965A (ru) 2018-02-28
RU2016133965A3 true RU2016133965A3 (fr) 2018-09-27
RU2711452C2 RU2711452C2 (ru) 2020-01-17

Family

ID=49999759

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016133965A RU2711452C2 (ru) 2014-01-22 2015-01-21 Усовершенствованная стратификация пациентов для оценки пригодности терапии

Country Status (7)

Country Link
US (1) US11199546B2 (fr)
EP (1) EP3097421B1 (fr)
JP (1) JP6700186B2 (fr)
CN (1) CN105917231B (fr)
BR (1) BR112016016675B1 (fr)
RU (1) RU2711452C2 (fr)
WO (1) WO2015110440A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017215983A1 (fr) * 2016-06-13 2017-12-21 Koninklijke Philips N.V. Procédé pour déduire l'activité d'un facteur de transcription d'une voie de transduction de signaux chez un sujet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708676D0 (en) * 1997-04-30 1997-06-18 Imp Cancer Res Tech Chemical compounds
WO2000066767A1 (fr) * 1999-04-30 2000-11-09 North Shore Long Island Jewish Health System Regulateurs du canal de signalisation des oestrogenes et utilisations correspondantes
DE19936618A1 (de) 1999-08-04 2001-03-15 Monotec Gmbh Diagnostisches Kit und dessen Verwendung
CA2663595A1 (fr) * 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Schemas proteomiques de pronostic du cancer et signatures predictives
WO2009089521A2 (fr) 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Prédicteurs pour évaluer une réponse à une thérapie du cancer
EP2304436A1 (fr) 2008-07-10 2011-04-06 Nodality, Inc. Procédés de diagnostic, pronostic et traitement
WO2010088386A1 (fr) 2009-01-28 2010-08-05 University Of Notre Dame Du Lac Test de récidive à progression accélérée
DE102009034665A1 (de) 2009-07-24 2011-01-27 Neumayer Tekfor Holding Gmbh Befestigungsvorrichtung und Befestigungssystem
JP5808349B2 (ja) * 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
PL2845911T3 (pl) * 2010-03-31 2017-01-31 Sividon Diagnostics Gmbh Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego
US20150212087A1 (en) 2012-07-27 2015-07-30 Centre Leon Berard Detection of the ERalpha/Src/PI3K Complex as Predictive Marker in Breast Cancer

Also Published As

Publication number Publication date
US20160334405A1 (en) 2016-11-17
BR112016016675B1 (pt) 2024-01-16
CN105917231B (zh) 2021-05-11
BR112016016675A2 (fr) 2017-08-08
RU2711452C2 (ru) 2020-01-17
RU2016133965A (ru) 2018-02-28
WO2015110440A1 (fr) 2015-07-30
EP3097421B1 (fr) 2019-11-13
CN105917231A (zh) 2016-08-31
US11199546B2 (en) 2021-12-14
EP3097421A1 (fr) 2016-11-30
JP6700186B2 (ja) 2020-05-27
JP2017508137A (ja) 2017-03-23

Similar Documents

Publication Publication Date Title
BR112016027525A2 (fr)
BR112016027506A2 (fr)
BR112016017201A2 (fr)
BR112016016546A2 (fr)
JP1518958S (fr)
BR112016026300A2 (fr)
BR112016026807A2 (fr)
BR112016016689A2 (fr)
BR112016021197A2 (fr)
BR112016023487A2 (fr)
RU2016143671A3 (fr)
BR112016022105A2 (fr)
BR112016027088A2 (fr)
BR112016022869A2 (fr)
BR112016030436A2 (fr)
BR112016026370A2 (fr)
BR112016026977A2 (fr)
BR112016022817A2 (fr)
BR112014024551A2 (fr)
BR112016022605A2 (fr)
RU2016151121A3 (fr)
BR112016026720A2 (fr)
BR112016027471A2 (fr)
RU2016133686A3 (fr)
BR112016015133A2 (fr)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20210122